Skip to main content

Table 7 Trough levels of total IgG at the end of treatment periods

From: Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Treatment interval Patient number (n) Geometric mean (95 % CI) Median (95 % CI) Min; max
IGIV 10 %
 3 weeks   19 11.58 (10.36–12.94) 12.00 (11.00–14.10) 5.45;14.50
 4 weeks   50 10.19 (9.55–10.88) 10.20 (9.61–11.30) 6.09;18.50
IGSC 20 %
 1 week 145 % of IV dose 27 14.77 (13.86–15.74) 15.30 (12.80–16.10) 12.00;20.30
 1 week Adjusted dose (145 % of IV dose) 66 14.20 (13.48–14.96) 14.65 (13.80–15.60) 8.65;22.20
 1 week Individualized dosea 57 14.74 (14.03–15.48) 15.10 (14.00–16.40) 8.81;23.40
  1. 95 %CI 95 % confidence interval
  2. aDetermined for each patient by comparing the individual serum IgG trough level attained in period 3 to the expected increase in serum IgG trough level calculated from the PK data from periods 1 and 2